New drug aims to tame rare artery disease
NCT ID NCT07477795
First seen Mar 20, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This phase 2 trial tests whether secukinumab, a drug that blocks IL-17A, can help people with active severe Takayasu arteritis achieve remission and stop taking steroids. About 52 participants will receive either secukinumab injections or standard care (like TNF inhibitors). The main goal is to see if more patients reach remission at 6 months without steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secukinumab (a drug that blocks IL-17A, given as injections under the skin)
What this could lead to
If it works, this could offer a new treatment option for severe Takayasu arteritis, helping patients achieve remission and reduce reliance on steroids.
What could go wrong
This is a small, early-phase (Phase 2) study with only 52 participants. Previous similar drugs have failed in larger trials, and the drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.